Treatment drug for autoimmune diseases and allergic diseases

Abstract

The present invention provides an agent for the prophylaxis or therapy of autoimmune diseases or allergic diseases, which contains an anti-Embigin antibody, particularly an anti-Embigin antibody showing cytotoxicity or a cytotoxicity inducing activity, an agent for the prophylaxis or therapy of diseases involving Th17 cell, and a cytotoxic agent to Th17 cell. In addition, an agent for detection of Th17 cell, which contains an anti-Embigin antibody, a convenient detection method of Th17 cell, which uses the agent, a method of efficiently delivering a drug and the like in a Th17 cell selective manner, which uses an anti-Embigin antibody, and a drug delivery system to Th17 cell are provided.

1 . A method for inducing a cellular damage in a Th17 cell, comprising contacting an anti-Embigin antibody to the Th17 cell. 
     
     
         2 . The method according to  claim 1 , wherein the anti-Embigin antibody has a cytotoxicity or a cytotoxicity inducing activity. 
     
     
         3 . The method according to  claim 1 , wherein the anti-Embigin antibody has a cytotoxicity inducing activity. 
     
     
         4 . The method according to  claim 3 , wherein the subclass of the anti-Embigin antibody having the cytotoxicity inducing activity is IgG1, IgG3 or IgM. 
     
     
         5 . The method according to  claim 1 , wherein the anti-Embigin antibody has a cytotoxicity. 
     
     
         6 . The method according to  claim 5 , wherein the anti-Embigin antibody having the cytotoxicity is conjugated with a cytotoxic substance, a chemotherapeutic agent or a radioisotope.